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Abstract
Background/Purpose
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life threatening hyperinflammatory
syndrome. Sinusoidal hemophagocytosis is occasionally observed on liver biopsy in
patients who do not have clinical suspicion of HLH. We aimed at comparing the clinical char-
acteristics and outcomes of patients with signs of hemophagocytosis on liver biopsy meeting
and not meeting the HLH diagnostic criteria.
Methods
We reviewed the clinical, laboratory features and outcomes of all adult patients consecu-
tively admitted in our center between 08/2011 and 08/2017 presenting with liver histology
showing sinusoidal hemophagocytosis and of critically ill patients presenting with severe
liver disease in whom hemophagocytosis was histologically confirmed. The characteristics
of patients fulfilling and not fulfilling the diagnostic criteria of HLH were compared.
Results
We identified 12 cases (58% male, median age 61, 75% with a chronic underlying disease)
with liver histology showing sinusoidal hemophagocytosis. All had at least some of the clini-
cal features typically associated with HLH. Six were critical ill patients. In 4 cases with insuffi-
cient laboratory and clinical criteria, liver biopsy allowed to confirm the HLH diagnosis. Six
patients died, of which four met the diagnostic criteria for HLH. Two patients with chronic
liver disease died despite not fulfilling the diagnostic criteria of HLH.
Conclusion
Hemophagocytosis on liver biopsy may contribute to confirming a diagnosis of HLH in sus-
pected cases with indeterminate clinical and laboratory findings. Sinusoidal hemophagocy-
tosis in patients with cirrhosis was associated with bad outcome.
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Introduction
Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome, is a
rare, life threatening hyperinflammatory syndrome characterized by excessive activation of
histiocytes and T lymphocytes leading to highly active but ineffective immune response [1].
HLH is classified into primary and secondary forms. Primary HLH is associated with different
genetic defects in cytotoxic pathway that typically occur before age 18 but has been described
in adults up to age 60 [2]. In contrast, secondary or acquired HLH is seen in adults who have
no underlying family history, showing however other underlying conditions which can induce
strong immunological stimulation, such as haematological or solid malignancies, infections,
rheumatic diseases and autoimmune diseases [3]. Infections associated with HLH are most fre-
quently caused by viruses (e.g. Epstein-Barr, Cytomegalovirus, Herpes simplex), but bacterial,
fungal, and parasites have also been described [4]. HLH symptoms may initially mirror those
observed in an infection (fever, malaise and fatigue). However, in patients with HLH the sub-
sequent hyperinflammatory response is fatal in a high percentage of cases if left untreated (50–
100% depending on the underlying condition) [1]. Diagnosing HLH is the critical step toward
successful therapy, which is currently based on corticosteroids associated with other immuno-
suppressant drugs [5].
Despite increasing insights into its genetic and immunologic basis [5]], HLH is still diag-
nosed based on a combination of clinical and laboratory findings (Table 1).
Many of these findings are nonspecific and are commonly observed systemic inflammatory
response syndrome. In a landmark prospective international treatment study of HLH in chil-
dren, the Histiocyte Society suggested five diagnostic criteria: fever, splenomegaly, bicytopenia
(neutro- and thrombocytopenia), hypertriglyceridemia and/or hypofibrinogenemia, and
hemophagocytosis in target organs (bone marrow, liver, spleen and lymph nodes) [7]. Subse-
quently, three additional criteria have been added [6]: hyperferritinemia, low/absent NK-cell-
activity, and high-soluble interleukin-2-receptor (CD25) levels. Among the eight criteria, five
must be fulfilled to diagnose HLH according to the HLH-2004 guidelines [6].
Table 1. Diagnostic criteria for HLH used in the HLH-2004 trial�. The diagnosis of HLH is established when 5 of
the 8 criteria listed below are fulfilled.
1. Fever � 38.5˚C
2. Splenomegaly
3. Cytopenias (affecting at least 2 of 3 lineages in the
peripheral blood)
Hemoglobin < 9 g/dL; Platelets < 100 x 103/mL;
Neutrophils < 1 x 103/mL
4. Hypertriglyceridemia and/or hypofibrinogenemia fasting, > 265 mg/dL
<150 mg/dL
5. Hemophagocytosis in bone marrow, spleen, lymph nodes, or liver
6. Low or absent NK-cell activity
7. Ferritin > 500 μg/L ‡
8. Elevated sCD25 (alpha-chain of sIL-2 receptor) §
�modified from Henter et al. [6]]
Notes
‡Although the HLH-2004 protocol uses ferritin > 500 μg/L, higher values should prompt a higher clinical suspicion,
namely ferritin > 3000 μg/L might be seen as suspicious of HLH and ferritin > 10 000 μg/L as highly suspicious for
HLH.
§Elevations above age-adjusted, laboratory-specific normal levels (defined as > 2 SD from the mean) appear more
meaningful than the original designation of >2400 U/mL because of variations between laboratories.
https://doi.org/10.1371/journal.pone.0226899.t001
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transplantation; MOF, multi-organ failure; ACLF,
acute on chronic liver failure.
These criteria have been developed to diagnose HLH in children, but are usually adopted in
adults as well since no specific study is available [8, 9]. In particular it has been suggested that
ferritin levels above 10,000 μg /L are accurate for HLH diagnosis, and could be used to prompt
further tests in adults [10]; this has been recently questioned [11] and hyperferritinemia alone
should never be used to diagnose HLH. Special tests such as NK cell function (no longer done
routinely) and soluble CD25 (alpha chain of the IL-2 receptor, marker of T-cell activation) as
well as sCD163 (marker of macrophage activation) and CD107a (marker of degranulation)
which more consistently correlated with the disease activity [9] are not available in all laborato-
ries and cannot be usually immediately obtained. Therefore, treatment delay is frequent.
Despite the fact that elevated liver enzymes are found in 98% of cases of HLH [12], little is
known regarding liver-related aspects of HLH in adults. Some cases presenting as acute hepati-
tis have been reported [13, 14], and occasionally, acute liver failure (ALF) may dominate the
clinical presentation [15, 16].
Liver biopsy can reveal activated macrophages with hemophagocytosis (any hemopoietic
cell included in the histiocyte, but most typically red cells and/or platelets) [17]. In primary,
pediatric forms of HLH, liver histopathology shows a characteristic pattern with a portal and
sinusoidal infiltrate of CD3+, CD8+, granzyme B+ lymphocytes admixed with CD68+, CD1a-
(benign but activated) histiocytes that exhibit hemophagocytosis [18, 19]. Typically, endothe-
lialitis of portal and central veins and lymphocyte-mediated bile duct injury is observed, and
the degree of portal and sinusoidal lympho-histiocytic infiltrate and endothelialitis varies from
mild to marked and correlates with clinical severity [17]. Interestingly, in one autoptic study
conducted in children with primary HLH, bone marrow biopsy was often negative, while liver
biopsy consistently showed “chronic hepatitis like” portal lymphocyte infiltrate, suggesting
that findings at liver biopsy might be more sensitive for the diagnosis of HLH [19].
Given the disease’s nonspecific feature, its diagnosis in patients presenting with liver
involvement is difficult and requires exclusion of more common conditions and histological
confirmation.
On the other hand, in patients presenting with acute liver disease, but lacking the classical
clinical diagnostic criteria of HLH syndrome, histological findings of sinusoidal hemophago-
cytosis are occasionally seen on liver biopsy and are considered non-specific for HLH [20], but
the clinical relevance of these findings is largely unclear.
The purpose of this study is to describe the clinical features and outcomes of patients con-
secutively admitted in our center in the period 08/2011-08/2017 in whom liver histology
showed sinusoidal hemophagocytosis (irrespective of whether HLH was eventually diag-
nosed). We aimed to compare patients’ clinical characteristics in those with and without sec-
ondary HLH according to the established HLH diagnostic criteria. Furthermore, we evaluated
in how many of our adult cases the presence of sinusoidal hemophagocytosis on liver biopsy
was a valuable additional diagnostic criterion.
Materials and Methods
This was a single center, retrospective study conducted at Inselspital, University of Bern, Swit-
zerland, in adult patients. This study has been approved by the Ethic Committee of the Canton
of Bern (KEK-BE: 2017–00148) and informed consent was not required. All procedures fol-
lowed were in accordance with the ethical standards of the responsible committee on human
experimentation (institutional and national) and with the Helsinki Declaration of 1975, as
revised in 2008. Cases were identified and collected in a 6 year period, from 08/2011 to 08/
2017 by accessing the Pathology Institute of the University of Bern (electronic record system
last accessed on August 10, 2017) identifying cases showing sinusoidal hemophagocytosis on
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liver histology; and by reviewing all adult patients with critically ill disease presenting with
severe liver disease (MELD score [21]�15 and/or Child-Pugh class C) in whom HLH was his-
tologically confirmed on any tissue (recorded at the hepatology unit of our center). Clinical,
radiological and laboratory data were retrieved from the electronic record system of Inselspital
(CGM Phoenix, Compu Group Medical Schweiz, AG). We retrospectively reviewed the
patients’ medical records and retrieved information regarding their underlying diseases, possi-
ble triggers of hemophagocytosis, clinical features, laboratory data, treatment and outcome.
We assessed the criteria recommended by the Histiocyte Society (Table 1) and calculated the
Score of Saint Antoine (Hscore) [22] using the online calculator: http://saintantoine.aphp.fr/
score/. Furthermore, we evaluated the presence of sinusoidal hemophagocytosis as possible
additional diagnostic criterion to be used in adults. Soluble CD25 and NK were not quantified
in the presented patients. On liver biopsy samples, the presence of sinusoidal hemophagocyto-
sis was reviewed by a single experienced pathologist. Ascertained by haematoxylin and eosin
(HE) staining; quantification of number of foci of hemophagocytosis per 20x field was per-
formed. Immunohistochemistry CD68 staining was made to better identify activated macro-
phages. The number of CD68 positive macrophages per high power field was determined.
Cases of primary HLH were excluded from this analysis.
Statistical analysis
Numerical data are described using median, interquartile range (IQR) and range, and percent-
ages are given when required. Non-parametric tests were used to compare numerical parame-
ters, and to obtain correlations between clinical and laboratory parameters and findings on
histology. All tests are 2-sided and p<0.05 was considered significant. Statistical analysis was
performed using PAWS statistics version 23 for Windows (SPSS Inc, Chicago, IL, USA).
Results
We identified 12 cases with liver histology showing sinusoidal hemophagocytosis. Most of
them were male (58%). The median age was 61 (IQR 26; range 22–81) years old. Seven patients
(58%) were older than 70. Ten patients (83%) had an underlying chronic disease, which in 2
cases was diagnosed during the hospital admission.
Table 2 summarizes the clinical and laboratory features of the study population.
In all cases the records showed a detailed workup of all relevant differential diagnoses,
including sepsis (microbiology workup) and evaluation of the anemia (Coombs test, LDH,
haptoglobin, unconjugated bilirubin, schistocytes).
Signs of sinusoidal hemophagocytosis detected on liver biopsy were rare in our center,
being this finding seen in approximately 0.3% of all liver biopsies performed in the study
period (n = 3855). However, seven of the cases were diagnosed in the last two years suggesting
an increased awareness of HLH and the association of this pathologic finding to HLH.
Reasons for liver biopsy in our patients were increased acute or chronic liver function tests
(n = 8), or fever of unknown origin associated with alteration of liver function tests.
Clinical and laboratory features of patients meeting the HLH diagnostic
criteria
Six patients (three males; median age 71 years; IQR 32; range 22–74) met the diagnostic criteria
for HLH (Table 2); in three of them (50%), the HLH diagnosis was made after performing
transjugular liver biopsy, upon the finding of sinusoidal hemophagocytosis. Interestingly, in
two cases (case 6 and 7) the Hscore was low- namely 119 and 127- reflecting a<10% risk of
HLH.
Hepatic sinusoidal hemophagocytosis
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All patients but one were severely ill on admission, and all but one (patient 6, who was also
not severely ill) had underlying chronic diseases: two had autoimmune diseases on chronic
immunosuppressive therapy (ulcerative colitis in one; systemic lupus erythemathodes and sec-
ondary antiphospholipid syndrome in one) and three had hematological diseases (Chronic
lymphocitic leukemia and Evans Syndrome in one; anaplastic lymphoma–that was diagnosed
during the hospitalization- in one, and pure white cell aplasia in one). All patients but one
(patient 9) presented with high fever, in four cases associates with pancytopenia. In three
patients bone marrow biopsy was performed and did not show signs of hemophagocytosis.
The most common diagnosis on admission was sepsis.
All cases showed increase in LFTs; usually, transaminases were moderately increased (2–10
times the upper limit of normality). All patients showed hypoalbuminemia. Jaundice was pres-
ent in three patients on admission and developed in all cases but one during the course of the
hospitalisation.
A possible infectious trigger for HLH was identified in 5 patients.
The median time interval between the hospital admission and liver biopsy was 11 days
(IQR 18; range 2 to 25). The time from hospital admission to the histological diagnosis was sig-
nificantly shorter in patients presenting with higher ferritin and higher alkaline phosphatase
(ALP) (5 days vs. 21 days in median; p = 0.03).
All patients received antibiotics, two of them received additionally antivirals treatment (i.e.
ganciclovir) aimed at controlling a suspected (in one case) or diagnosed (in another case)
underlying CMV infection. Five patients received immunosuppressants (steroids and etopo-
side in three, steroids and anti-IL1 in one, cyclosporin in one). The immunosuppressive ther-
apy was ongoing since the hospitalization in three cases, while a specific therapy was started in
three patients respectively 2, 6 and 13 days after the admission, as soon as the report of the
liver biopsy became available (on the same day or on the following day). Four patients (67%)
died during the hospitalization, while two (case 2 and 6) recovered. One of the survivors (case
2) showed a chronic slight elevation of cholestasis enzymes on follow-up. A second liver biopsy
was obtained one year after the first admission and showed again signs of sinusoidal
hemophagocytosis.
Clinical and laboratory features of patients not meeting the HLH
diagnostic criteria
Six patients (4 males; median age 68 years; IQR 33; range 24–81) did not meet the diagnostic
criteria for HLH (Table 2). The laboratory parameters on admission (AST, ALT, ALP, GGT,
albumin, INR, creatinine, hemoglobin, platelet count) were similar to those of patients fulfill-
ing the diagnostic criteria of HLH, and despite similar signs and symptoms, patients were less
severely ill (only one patient was initially admitted to the ICU due to critical illness). Median
Hscore was 149 points (IQR 75; range 90–190), with in median 3 criteria fulfilled (IQR 2;
range 1–4). Similarly to patients fulfilling the diagnostic criteria of HLH, all patients but one
had underlying chronic diseases: autoimmune conditions in three, hematological malignancy
in one, and alcoholic cirrhosis with portal hypertension (large varices on endoscopy) in one;
only this latter patient was severely ill on admission. One patient had a suspected hemolytic-
uremic syndrome and one had a CMV infection as potential infectious triggers of their severe
inflammatory status. In one case (Patient 8) in addition to sinusoidal hemophagocytosis find-
ings on liver biopsy (fifth positive criterion for HLH), there were also signs suggesting autoim-
mune hepatitis. Bone marrow biopsy did not show signs of HLH. Furthermore, this patient
showed a fast response to corticosteroids. The diagnosis of HLH was then considered unlikely.
Three patients (one previously diagnosed with cirrhosis-case 3, and one with signs of advanced
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chronic liver disease on liver biopsy- case 4) had clinically evident, moderate ascites on presen-
tation. All patients showed hypoalbuminemia and all patients were jaundiced on admission.
Increase in transaminases was usually mild to moderate and very elevated values of AST or
ALT (>15 times the upper limit of normality) were observed only in the patient diagnosed
with autoimmune hepatitis (case 12) [23]. Two patients (33%), both with underlying advanced
liver disease, became critically ill during the hospitalization and died. Four patients, including
the two who died, received steroids as part of their treatment.
Histological findings of liver biopsy, correlation with clinical presentation
and outcome
Two patients with a definite diagnosis of HLH and two not fulfilling the criteria for HLH
showed sinusoidal dilatation. None of the patients with HLH had fibrosis, while three of the
patients not fulfilling the criteria for HLH showed some extent of liver fibrosis (non-septal in
one, septal in two). Three patients with HLH showed centrolobular necrosis and one patient
without HLH showed intralobular necrosis. A plasma cell infiltrate was observed in one
patient with HLH, and in two patients without HLH; one additional patient without HLH
showed mixed inflammatory cells infiltrate.
As far as the sinusoidal hemophagocytosis findings, histology and immunohistochemistry
showed similar findings, irrespective of whether a final diagnosis of HLH was made.
Fig 1 shows representative images HE staining revealed mononuclear cells infiltration in
the portal tract and sinusoids.
Immunohistochemistry showed numerous CD68 positive macrophages, which, on HE
staining, presented clear signs of hemophagocytosis. An exception was represented by a
patient (case 12) presenting with features of autoimmune hepatitis associated with sinusoidal
hemophagocytosis.
Increased AST on presentation positively correlated with the number of foci of hemopha-
gocytosis on liver biopsy (Spearman’s rho: 0.773, p = 0.015) (Fig 2).
Mortality in patients with sinusoidal hemophagocytosis
As discussed above, in the present series of sinusoidal hemophagocytosis on liver biopsy, 50%
(n = 6) died, mostly within one month since hospital admission (median 12 days; IQR 21;
range 10 to 36). Irrespective of whether a final diagnosis of HLH was determined during
admission, all patients who died, had severe underlying chronic diseases, and in all cases at
admission a typical presentation including high fever, hepato-splenomegaly and bicytopenia
was present (Table 2). With the limitation of a small number of events, none of the laboratory
findings was statistically associated with fatal outcome, even if ferritin tended to be higher in
patients who were deceased in comparison to survivors (median: 25’516 vs.10’536 μg/L).
Discussion
Hemophagocytic lymphohistiocytosis (HLH), or haemophagocytic syndrome is a life-threat-
ening disease with a reported mortality of over 50% [3], belonging to the so-called “cytokine
storm syndromes”. In HLH, following a strong immunological stimulus, the uncontrolled pro-
liferation of activated macrophages and lymphocytes leads to the secretion of a massive
amount of inflammatory cytokines, which are thought to explain the organ damage [1]]. In
patients with infection-triggered HLH, initial symptoms are non-specific, and the diagnosis of
HLH can be challenging. [1, 4]]. Patients with HLH, however, cannot control the hyperinflam-
matory response which, if left untreated, is often fatal [1, 2, 24].
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Despite its rarity, HLH is observed in up to 1% of patients with hematologic malignancy
[24]] and has a dismal prognosis if left untreated. Clinical suspicion is key to drive the work-
up recommended to diagnose HLH, which includes standard laboratory tests, specific tests
and biopsy of organs that can be affected by the hemophagocytosis process.
In the largest series published so far in adult patients with HLH, alteration of LFTs is almost
invariably observed [12, 25]], and AST/ALT elevation is considered among the criteria used to
calculate the Hscore [22]]. Despite this, few cases of HLH presenting mainly as liver disease
Fig 1. Liver biopsy showing signs of sinusoidal hemophagocytosis (arrows). Panel A and Panel B: HE (100x) patient with HLH syndrome. Panel C: HE
(100x) patient fulfilling 3 diagnostic criteria of HLH syndrome. Panel D. IHC for CD68 (20x) showing multiple cells expressing CD68.
https://doi.org/10.1371/journal.pone.0226899.g001
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have been described in the literature [13, 14, 16, 25], and the significance of signs of hemopha-
gocytosis observed in liver biopsy in patients not fulfilling the classical diagnostic criteria for
HLH is currently unknown.
It has been previously reported that findings of hemophagocytosis in bone marrow aspi-
rates is frequent even in subjects without HLH [26]. In our study focusing on liver biopsy,
signs of hemophagocytosis were rarely found among all reviewed specimens. Our findings
might suggest that the liver is less often involved, or later affected in the immunological pro-
cesses leading to HLH. Given that liver biopsy is not frequently performed on suspicion of
HLH, further studies with a larger number of patients would be valuable to confirm our find-
ings. On the other hand, sinusoidal hemophagocytosis might be overlooked if not specifically
sought; we observed an increase in the number of diagnosed cases at our center in the last two
years, supporting an increased awareness for this sign and for HLH. It should be underlined
that the finding of sinusoidal hemophagocytosis does not imply a diagnosis of HLH as this
finding is considered non-specific and is present in other conditions characterized by immune
activation such as sepsis [20]. In our series, half of the cases showing sinusoidal hemophagocy-
tosis fulfilled the diagnostic criteria of HLH. Importantly, liver biopsy led to the definitive diag-
nosis of HLH in three patients in whom clinical and laboratory HLH diagnosis criteria were
not otherwise fulfilled. It has to be taken into account that the diagnostic performance of
Hscore in adults is debated [27]. However, a correct diagnosis ruling-out or ruling-in HLH is
key, on one side to avoid immunosuppression when it is not needed, on the other side since
newer therapies such as interferon gamma inhibitors may make a difference to outcomes in
Fig 2. Correlation of AST and number of sinusoidal hemophagocytosis foci; observed at 20x on liver biopsy (Spearman’s Rho r = 0.773, p = 0.015).
https://doi.org/10.1371/journal.pone.0226899.g002
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the future. The finding of sinusoidal hemophagocytosis can be considered an important diag-
nostic feature to be searched in adults upon clinical suspicion of HLH and indeterminate labo-
ratory findings, and we suggest that transjugular liver biopsy can be considered as a further
diagnostic tool to provide an additional indicator supporting HLH diagnosis and comple-
menting clinical acumen and laboratory tests. In this regard, it should be underlined that
transjugular liver biopsy is a safe procedure, even in patients with severe thrombocytopenia
and coagulopathy [28]. We acknowledge that since liver biopsy is not routinely performed in
patients already diagnosed with HLH at our center, we cannot provide data regarding the sen-
sitivity of liver biopsy in the context of HLH, meaning that we do not know if patients with
HLH might show negative results (no sinusoidal hemophagocytosis) on liver biopsy.
As for the patients showing sinusoidal hemophagocytosis but not fulfilling the diagnostic
criteria for HLH, the clinical presentation was usually less severe as compared to patients ful-
filling the criteria for HLH. On the other hand, both groups shared several features, including
similar values of laboratory tests, and presence of underlying chronic diseases frequently asso-
ciated with HLH [1, 6, 7]. This suggests that sinusoidal hemophagocytosis in the absence of
HLH might indicate uncontrolled hepatic/systemic inflammation, leading to clinical features
closely resembling HLH.
Regarding liver-related findings, most of the patients showed a mild to moderate increase
of AST/ALT. A novel, interesting finding of the present study is that AST at presentation
closely correlated with the severity of histological signs of hemophagocytosis, suggesting that
monitoring AST on treatment might help in evaluating the inflammatory activityitself, and
potentially in assessing treatment efficacy. Confirmation of this correlation in a larger number
of patients would be of interest.
All our patients showed hypoalbuminemia. In our view, even if this is a non-specific find-
ing, it should be included among those appearing in adult HLH, similarly to what is already
done in children suspected of HLH[29].
Similarly to what occurs in patients with sepsis, jaundice (total bilirubin > 50μmol/L) was
present at admission or developed over the course of the hospital admission in all patients with
signs of hemophagocytosis but one, likely reflecting the effects of pro-inflammatory cytokines
on several steps of bile flow (down regulation of bile acid transporters [30]; oxidative stress
leading to the inhibition of cAMP-dependent transport function [31] eventually leading to
intrahepatic cholestasis.
Interestingly, the number of CD68 macrophages on histology did not correlate with the
number of positive foci. Consequently, the number of CD68 positive cells does not seem useful
to demonstrate liver involvement in hemophagocytosis, which relies mostly on haematoxylin
and eosin.
In agreement with previous reports regarding a very high mortality in patients with HLH
[1, 12, 24], four patients with HLH included in our series died, all of them within approxi-
mately one month after being hospitalized. Similarly to the report by Li et al [12], all patients
who died in our series presented typically with high fever, hepato-splenomegaly and bicytope-
nia, which should be considered as ominous prognostic signs. In addition, two patients with
sinusoidal hemophagocytosis not fulfilling the diagnostic criteria for HLH died.
These patients had either a known cirrhosis or advanced liver disease on liver biopsy and
presented with ascites. This suggest that in patients with cirrhosis—in whom immune-
response is altered [32, 33]—hemophagocytosis likely indicates a particularly severe inflamma-
tory activation, which might explain a very severe acute- on- chronic liver failure.
A novel observation in our series concerns the finding of signs of hemophagocytosis in a
follow-up liver biopsy obtained one year after discharge in the patient surviving a first episode
of HLH (triggered by viral and bacterial infection; case 2). Interestingly, bone marrow biopsy
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at the time of first diagnosis was negative. To our knowledge, chronic secondary hemophago-
cytosis in the liver has never been reported so far. Whether this might be linked to a genetic
component with a liver-specific behavior is currently unknown.
In conclusion, signs of hemophagocytosis on liver biopsy can be found in patients fulfilling
or not the diagnostic criteria for HLH. Mortality in HLH was very high in this series. In sub-
jects in whom HLH is suspected transjugular liver biopsy might be considered since it can pro-
vide findings supporting a HLH diagnosis complementing clinical acumen and laboratory
tests. Patients not fulfilling the diagnostic criteria for HLH showed similar risk factors and trig-
gers as patients with HLH and two of them had a fatal outcome, suggesting that sinusoidal
hemophagocytosis in the absence of HLH might still indicate uncontrolled hepatic and sys-
temic inflammation, leading to clinical features closely resembling HLH. Signs of hemophago-
cytosis on histology in patients with a history of chronic liver disease seem to be an ominous
prognostic sign even in the absence of HLH. Irrespective of whether a diagnosis of HLH is
eventually made, all patients with suspected HLH and patients with findings of sinusoidal
hemophagocytosis on liver biopsy should receive an extensive work-up aimed at identifying
possible triggers amenable to treatment.
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